Carl R. Flannery
Pfizer
200 CambridgePark Drive
Cambridge
MA 02140
USA
Name/email consistency: high
- Novel therapies in OA. Flannery, C.R. Curr. Drug. Targets (2010)
- Prevention of cartilage degeneration in a rat model of osteoarthritis by intraarticular treatment with recombinant lubricin. Flannery, C.R., Zollner, R., Corcoran, C., Jones, A.R., Root, A., Rivera-Bermúdez, M.A., Blanchet, T., Gleghorn, J.P., Bonassar, L.J., Bendele, A.M., Morris, E.A., Glasson, S.S. Arthritis Rheum. (2009)
- MMPs and ADAMTSs: functional studies. Flannery, C.R. Front. Biosci. (2006)
- Usurped SLRPs: novel arthritis biomarkers exposed by catabolism of small leucine-rich proteoglycans?. Flannery, C.R. Arthritis Res. Ther. (2006)
- Autocatalytic cleavage of ADAMTS-4 (Aggrecanase-1) reveals multiple glycosaminoglycan-binding sites. Flannery, C.R., Zeng, W., Corcoran, C., Collins-Racie, L.A., Chockalingam, P.S., Hebert, T., Mackie, S.A., McDonagh, T., Crawford, T.K., Tomkinson, K.N., LaVallie, E.R., Morris, E.A. J. Biol. Chem. (2002)